Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 27;2(2):CD012922.
doi: 10.1002/14651858.CD012922.pub2.

Pharmacological treatment for central sleep apnoea in adults

Aline Rocha  1 , Ana Carolina Pereira Nunes Pinto  2 , Daniela V Pachito  3 , Luciano F Drager  4   5 , Geraldo Lorenzi-Filho  6 , Álvaro N Atallah  7
Affiliations

Pharmacological treatment for central sleep apnoea in adults

Aline Rocha et al. Cochrane Database Syst Rev. .

Abstract

Background: The term central sleep apnoea (CSA) encompasses diverse clinical situations where a dysfunctional drive to breathe leads to recurrent respiratory events, namely apnoea (complete absence of ventilation) and hypopnoea sleep (insufficient ventilation) during sleep. Studies have demonstrated that CSA responds to some extent to pharmacological agents with distinct mechanisms, such as sleep stabilisation and respiratory stimulation. Some therapies for CSA are associated with improved quality of life, although the evidence on this association is uncertain. Moreover, treatment of CSA with non-invasive positive pressure ventilation is not always effective or safe and may result in a residual apnoea-hypopnoea index.

Objectives: To evaluate the benefits and harms of pharmacological treatment compared with active or inactive controls for central sleep apnoea in adults.

Search methods: We used standard, extensive Cochrane search methods. The latest search date was 30 August 2022.

Selection criteria: We included parallel and cross-over randomised controlled trials (RCTs) that evaluated any type of pharmacological agent compared with active controls (e.g. other medications) or passive controls (e.g. placebo, no treatment or usual care) in adults with CSA as defined by the International Classification of Sleep Disorders 3rd Edition. We did not exclude studies based on the duration of intervention or follow-up. We excluded studies focusing on CSA due to periodic breathing at high altitudes.

Data collection and analysis: We used standard Cochrane methods. Our primary outcomes were central apnoea-hypopnoea index (cAHI), cardiovascular mortality and serious adverse events. Our secondary outcomes were quality of sleep, quality of life, daytime sleepiness, AHI, all-cause mortality, time to life-saving cardiovascular intervention, and non-serious adverse events. We used GRADE to assess certainty of evidence for each outcome.

Main results: We included four cross-over RCTs and one parallel RCT, involving a total of 68 participants. Mean age ranged from 66 to 71.3 years and most participants were men. Four trials recruited people with CSA associated with heart failure, and one study included people with primary CSA. Types of pharmacological agents were acetazolamide (carbonic anhydrase inhibitor), buspirone (anxiolytic), theophylline (methylxanthine derivative) and triazolam (hypnotic), which were given for between three days and one week. Only the study on buspirone reported a formal evaluation of adverse events. These events were rare and mild. No studies reported serious adverse events, quality of sleep, quality of life, all-cause mortality, or time to life-saving cardiovascular intervention. Carbonic anhydrase inhibitors versus inactive control Results were from two studies of acetazolamide versus placebo (n = 12) and acetazolamide versus no acetazolamide (n = 18) for CSA associated with heart failure. One study reported short-term outcomes and the other reported intermediate-term outcomes. We are uncertain whether carbonic anhydrase inhibitors compared to inactive control reduce cAHI in the short term (mean difference (MD) -26.00 events per hour, 95% CI -43.84 to -8.16; 1 study, 12 participants; very low certainty). Similarly, we are uncertain whether carbonic anhydrase inhibitors compared to inactive control reduce AHI in the short term (MD -23.00 events per hour, 95% CI -37.70 to 8.30; 1 study, 12 participants; very low certainty) or in the intermediate term (MD -6.98 events per hour, 95% CI -10.66 to -3.30; 1 study, 18 participants; very low certainty). The effect of carbonic anhydrase inhibitors on cardiovascular mortality in the intermediate term was also uncertain (odds ratio (OR) 0.21, 95% CI 0.02 to 2.48; 1 study, 18 participants; very low certainty). Anxiolytics versus inactive control Results were based on one study of buspirone versus placebo for CSA associated with heart failure (n = 16). The median difference between groups for cAHI was -5.00 events per hour (IQR -8.00 to -0.50), the median difference for AHI was -6.00 events per hour (IQR -8.80 to -1.80), and the median difference on the Epworth Sleepiness Scale for daytime sleepiness was 0 points (IQR -1.0 to 0.00). Methylxanthine derivatives versus inactive control Results were based on one study of theophylline versus placebo for CSA associated with heart failure (n = 15). We are uncertain whether methylxanthine derivatives compared to inactive control reduce cAHI (MD -20.00 events per hour, 95% CI -32.15 to -7.85; 15 participants; very low certainty) or AHI (MD -19.00 events per hour, 95% CI -30.27 to -7.73; 15 participants; very low certainty). Hypnotics versus inactive control Results were based on one trial of triazolam versus placebo for primary CSA (n = 5). Due to very serious methodological limitations and insufficient reporting of outcome measures, we were unable to draw any conclusions regarding the effects of this intervention.

Authors' conclusions: There is insufficient evidence to support the use of pharmacological therapy in the treatment of CSA. Although small studies have reported positive effects of certain agents for CSA associated with heart failure in reducing the number of respiratory events during sleep, we were unable to assess whether this reduction may impact the quality of life of people with CSA, owing to scarce reporting of important clinical outcomes such as sleep quality or subjective impression of daytime sleepiness. Furthermore, the trials mostly had short-term follow-up. There is a need for high-quality trials that evaluate longer-term effects of pharmacological interventions.

PubMed Disclaimer

Conflict of interest statement

AR: none known ACP: none known DP: none known GLF: owns stocks in Biologix (a start‐up company producing a simple device for sleep apnoea diagnosis) AA: none known LD: paid consultant for ResMed Foundation

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Carbonic anhydrase inhibitors versus inactive control , Outcome 1: Central apnoea‐hypopnoea index (short‐term)
1.2
1.2. Analysis
Comparison 1: Carbonic anhydrase inhibitors versus inactive control , Outcome 2: Cardiovascular mortality (intermediate‐term)
1.3
1.3. Analysis
Comparison 1: Carbonic anhydrase inhibitors versus inactive control , Outcome 3: Apnoea‐hypopnoea index (short‐term)
1.4
1.4. Analysis
Comparison 1: Carbonic anhydrase inhibitors versus inactive control , Outcome 4: Apnoea‐hypopnoea index (intermediate‐term)
2.1
2.1. Analysis
Comparison 2: Methylxanthine derivative agents versus inactive control , Outcome 1: Central apnoea‐hypopnoea index (short‐term)
2.2
2.2. Analysis
Comparison 2: Methylxanthine derivative agents versus inactive control , Outcome 2: Apnoea‐hypopnoea index (short‐term)
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012922

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Bonnet 1990 {published data only}
    1. Bonnet MH, Dexter JR, Arand DL. The effect of triazolam on arousal and respiration in central sleep apnea patients. Sleep 1990;13(1):31-41. - PubMed
Giannoni 2020a {published data only}
    1. Giannoni A, Borrelli G, Mirizzi G, Richerson GB, Emdin M, Passino C. Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial. European Journal of Heart Failure 2020;23(2):312-20. - PubMed
Javaheri 1996 {published data only}
    1. Javaheri S, Parker TJ, Wexler L, Liming JD, Lindower P, Roselle GA. Effect of theophylline on sleep-disordered breathing in heart failure. New England Journal of Medicine 1996;335(8):562-7. - PubMed
Javaheri 2006 {published data only}
    1. Javaheri S, Sands SA, Edwards BA. Acetazolamide attenuates Hunter-Cheyne-Stokes breathing but augments the hypercapnic ventilatory response in patients with heart failure. Annals of the American Thoracic Society 2014;11:80-6. - PubMed
    1. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. American Journal of Respiratory and Critical Care Medicine 2006;173(2):234-7. - PubMed
Sorokina 2019a {published data only}
    1. Sorokina K, Poltavskaya M, Palman A, Kuklina M, Kharkevich K. Central sleep apnea in patients with chronic heart failure and its treatment with acetazolamide. European Journal of Heart Failure 2019;21(suppl.S1):P1678.

References to studies excluded from this review

Belyavskiy 2010 {published data only}
    1. Belyavskiy E, Kalinkin A, Mareev V. Acetazolamide improves severity of chronic heart failure in patients with obstructive sleep apnea syndrome. European Journal of Heart Failure 2010;9(Suppl 1):S196.
    1. Belyavskiy E, Litvin A, Mareev V. Effects of acetazolamide in patients with obstructive sleep apnea syndrome and chronic heart failure. European Heart Journal 2010;31(Suppl 1):857 [P4878].
    1. Belyavskiy E, Mareev V. Acetazolamide decreases obstructive sleep apnea severity in patients with chronic heart failure. European Journal of Heart Failure 2011;10:S30-1.
Caravita 2022 {published data only}
    1. Caravita S, Faini A, Vignati C, Pelucchi S, Salvioni E, Cattadori G, et al. Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure. European Journal of Heart Failure 2022;24(10):1940-9. [DOI: 10.1002/ejhf.2628] - DOI - PMC - PubMed
Connaughton 1984 {published data only}
    1. Connaughton JJ, Morgan AD, Douglas NJ. Central sleep apnoeas are not reduced by almitrine. Clinical Science 1984;66:4P.
DeBacker 1995 {published data only}
    1. DeBacker W, Verbraecken J, Willemen M, Wittsaele W, DeCock W, de Hayning P. Central apnea index decreases after prolonged treatment with acetazolamide. American Journal of Respiratory and Critical Care Medicine 1995;151(1):87-91. - PubMed
Dubowitz 1998 {published data only}
    1. Dubowitz G. Effect of temazepam on oxygen saturation and sleep quality at high altitude: randomised placebo controlled crossover trial. BMJ 1998;316(7131):587-9. - PMC - PubMed
Ginter 2020 {published data only}
    1. Ginter G, Sankari A, Eshraghi M, Obiakor H, Yarandi H, Chowdhuri S, et al. Effect of acetazolamide on susceptibility to central sleep apnea in chronic spinal cord injury. Journal of Applied Physiology 2020;128(4):960-6. - PMC - PubMed
Jaffuel 2021 {published data only}
    1. Jaffuel D, Nogue E, Berdague P, Galinier M, Fournier P, Dupuis M, et al. Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study. ESC Heart Failure 2021;8(4):2513-26. - PMC - PubMed
Javed 2020 {published data only}
    1. Javed F, Tamisier R, Pepin JL, Cowie MR, Wegscheider K, Angermann C, et al. Association of serious adverse events with Cheyne-Stokes respiration characteristics in patients with systolic heart failure and central sleep apnoea: a SERVE-Heart Failure substudy analysis. Respirology 2020;25(3):305-11. - PubMed
Murray 1977 {published data only}
    1. Murray GB. Carbamazepine for central sleep apnea. JAMA 1977;238(3):212-3. - PubMed
Naghan 2019 {published data only}
    1. Naghan PA, Raeisi K, Khoundabi B, Foroughi M, Malekmohammad M, Mohebbi M, et al. The effect of acetazolamide on the improvement of central apnea caused by abusing opioid drugs in the clinical trial. Sleep and Breathing 2019;24:1-9. [DOI: ] - PubMed
Naghan 2020 {published data only}
    1. Naghan PA, Raeisi K, Khoundabi B, Foroughi M, Malekmohammad M, Mohebbi M, et al. The effect of acetazolamide on the improvement of central apnea caused by abusing opioid drugs in the clinical trial. Sleep and Breathing 2020;24(4):1417-25. - PubMed
NCT00746954 {published data only}
    1. NCT00746954. Buspirone as a potential treatment for recurrent central apnea (CSA treatment). clinicaltrials.gov/ct2/show/NCT00746954 (first received 4 September 2008).
NCT01500473 {published data only}
    1. NCT01500473. Therapeutic effect of desogestrel on ventilatory control in patients with congenital central hypoventilation syndrome. clinicaltrials.gov/ct2/show/NCT01500473 (first received 28 December 2011).
NCT02670096 {published data only}
    1. NCT02670096. A single-center pilot study evaluating the immediate effects of low-dose acetazolamide on respiratory control in subjects with treatment emergent sleep disordered breathing. www.clinicaltrials.gov/ct2/show/NCT02670096 (first received 1 February 2016).
Obernadorfer 2000 {published data only}
    1. Obernadorfer S, Saletu B, Gruber G, Anderer P, Saletu M, Mandl M, et al. Theophylline in snoring and sleep-related breathing disorders: sleep laboratory investigations on subjective and objective sleep and awakening quality. Methods and Findings in Experimental and Clinical Pharmacology 2000;22(4):237-45. - PubMed
Passino 2021 {published data only}
    1. Passino C, Sciarrone P, Vergaro G, Borrelli C, Spiesshoefer J, Gentile F, et al. Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. International Journal of Cardiology 2021;330:112-9. - PubMed
Prowting 2021 {published data only}
    1. Prowting J, Maresh S, Vaughan S, Kruppe E, Alsabri B, Badr MS, et al. Mirtazapine reduces susceptibility to hypocapnic central sleep apnea in males with sleep-disordered breathing: a pilot study. Journal of Applied Physiology 2021;131(1):414-23. - PMC - PubMed
Rastogi 2020 {published data only}
    1. Rastogi R, Bakkila KA, Badr M, Chowdhuri S, Dingell JD. Effect of acetazolamide on pathophysiology of sleep disordered breathing in older adults. American Journal of Respiratory and Critical Care Medicine 2020;201:A6454.
Saletu 1999 {published data only}
    1. Saletu B, Oberndorfer S, Anderer P, Gruber G, Divos H, Lachner A, et al. Efficiency of continuous positive airway pressure versus theophylline therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality. Neuropsychobiology 1999;39:151-9. - PubMed
Schumacher 2014 {published data only}
    1. Schumacher DS, Müller-Mottet S, Hasler ED, Hildenbrand FF, Keusch S, Speich R, et al. Effect of oxygen and acetazolamide on nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary pulmonary hypertension and sleep-disturbed breathing. Chest 2014;146(5):1226-36. - PubMed
Schwarz 2020 {published data only}
    1. Schwarz EI, Kohler M. Randomized controlled trials on the comparative effect of treatment modalities of central sleep apnea with Cheyne-Stokes Respiration on cardiovascular outcomes and physiology studies required. Journal of Clinical Sleep Medicine 2020;16(4):653-4. - PMC - PubMed
Shore 1983 {published data only}
    1. Shore T, Millman P. Central sleep apnea and acetazolamide therapy. Archives of Internal Medicine 1983;143:1278. [DOI: 10.1001/archinte.1983.00350060210040] - DOI - PubMed
Sin 1999 {published data only}
    1. Sin D, Bradley D. Theophylline therapy for near-fatal Cheyne-Stokes respiration. Annals of Internal Medicine 1999;131(9):713-4. - PubMed
Sorokina 2019b {published data only}
    1. Sorokina KV, Palman AD, Brovko M, Poltavskaya MG. Central sleep apnea in patients with chronic heart failure. Journal of Neurology and Psychiatry 2019;119:99-104. - PubMed
Ulrich 2013 {published data only}
    1. Ulrich S, Keusch S, Hildenbrand F, Huber LC, Speich R, Tanner F, et al. Nocturnal oxygen therapy improves exercise performance in patients with pulmonary hypertension and sleep disturbed breathing compared to acetazolamide and placebo. Randomized, double-blind, cross-over trial. Respiration 2013;34:527. - PubMed
Ulrich 2015 {published data only}
    1. Ulrich S, Keusch S, Hildenbrand FF, Lo Cascio C, Huber LC, et al. Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. European Heart Journal 2015;36(10):615-22. - PubMed
Westwood 2012 {published data only}
    1. Westwood AJ, Vendrame M, Montouris G, Auerbach SH. Pearls & oy-sters: treatment of central sleep apnea with topiramate. Neurology 2012;78(16):e97-9. - PubMed
Yasuma 2006 {published data only}
    1. Yasuma F, Murohara T, Hayano J. Long-term efficacy of acetazolamide on Cheyne-Stokes respiration in congestive heart failure. American Journal of Respiratory and Critical Care Medicine 2006;174(4):479; author reply 479-80. - PubMed

References to studies awaiting assessment

Ahmad 2022 {published data only}
    1. Ahmad B, Aldwaikat A, Eshraghi M, Carroll SW, Lasisi O, Al-Maktar T, et al. Effect of zolpidem on susceptibility to develop central sleep apnea. American Journal of Respiratory and Critical Care Medicine 2021;203:A4748.
    1. Ahmad B, Sankari A, Eshraghi M, Aldwaikat A, Yarandi H, Zeineddine S, et al. Effect of zolpidem on nocturnal arousals and susceptibility to central sleep apnea. Sleep and Breathing 2022 Mar 14 [Epub ahead of print]. [DOI: 10.1007/s11325-022-02593-3] [PMID: ] - DOI - PMC - PubMed
Guo 2003 {published data only}
    1. Guo X, Chen W, Hongyu Z, Weimin K, Li A, Li L, et al. Effects of zolpidem on nocturnal breathing and sleep in normal and SAHS subjects. Sleep Medicine 2003;4(Suppl 1):S15.
NCT02569970 {published data only}
    1. NCT02569970. Efficacy of fluoxetine against seizure-induced central apneas (FLUOXETINE) [Efficacy of fluoxetine against seizure-induced central apneas: a randomized placebo-controled double-blind trial]. clinicaltrials.gov/ct2/show/NCT02569970 (first received 7 October 2015).
Sorokina 2022 {published data only}
    1. Sorokina KV, Poltavskaya MG, Palman AD, Kuklina MD, Kharkevich KY, Andreev AD, et al. Acetazolamide in the Cheyne Stokes respiration therapy in patients with chronic heart failure: a pilot randomized study. Human Physiology 2022;48(1):78-85.

References to ongoing studies

2015‐003119‐39 {published data only}
    1. 2015-003119-39. Effects of a short therpay of zolpidem with support servo-ventilation versus placebo in patients with central sleep apnea with chronic heart failure. www.clinicaltrialsregister.eu/ctr-search/search?query=2015-003119-39 (first received 29 October 2015).
NCT04118387 {published data only}
    1. NCT04118387. Central sleep apnea: physiologic mechanisms to inform treatment. clinicaltrials.gov/ct2/show/NCT04118387 (first received 8 October 2022).

Additional references

American Academy of Sleep Medicine 2014
    1. American Academy of Sleep Medicine. International Classification of Sleep Disorders. Darien, IL: American Academy of Sleep Medicine, 2014.
Aurora 2012
    1. Aurora RN, Chowdhuri S, Ramar K, Bista SR, Casey KR, Lamm CI, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. Sleep 2012;35(1):17-40. - PMC - PubMed
Benjafield 2019
    1. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet 2019;7(8):687-98. [PMID: ] - PMC - PubMed
Berssenbrugge 1983
    1. Berssenbrugge A, Dempsey J, Iber C, Skatrud J, Wilson P. Mechanisms of hypoxia-induced periodic breathing during sleep in humans. Journal of Physiology 1983;343:507-24. - PMC - PubMed
Brack 2007
    1. Brack T, Thüer I, Clarenbach CF, Senn O, Noll G, Russi EW, et al. Daytime Cheyne-Stokes respiration in ambulatory patients with severe congestive heart failure is associated with increased mortality. Chest 2007;135:1463-71. - PubMed
Bradley 2005
    1. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, et al. Continuous positive airway pressure for central sleep apnea and heart failure. New England Journal of Medicine 2005;19:2025-33. - PubMed
Buysse 1989
    1. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Research 1989;28(2):193-213. - PubMed
Carrero 2011
    1. Carrero JJ, Jager DJ, Verduijn M, Ravani P, De Meester J, Heaf JG, et al. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. Clinical Journal of the American Society of Nephrology 2011;6(7):1722-30. - PubMed
Cowie 2015
    1. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. New England Journal of Medicine 2015;373(12):1095-105. - PMC - PubMed
Eckert 2007
    1. Eckert DJ, Jordan AS, Merchia P, Malhotra A. Central sleep apnea: pathophysiology and treatment. Chest 2007;131(2):595-607. - PMC - PubMed
Emdin 2017
    1. Emdin M, Mirizzi G, Giannoni A, Poletti R, Iudice G, Bramanti F, et al. Prognostic significance of central apneas throughout a 24-hour period in patients with heart failure. Journal of the American College of Cardiology 2017;70(11):1351-64. - PubMed
EPOC 2017
    1. EPOC. Cochrane Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC Resources for review authors, 2017. epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/Resources... (accessed prior to 21 September 2022).
Fala 2015
    1. Fala L. Entresto (Sacubitril/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. American Health & Drug Benefits 2015;6:330-4. - PMC - PubMed
Giannoni 2009
    1. Giannoni A, Emdin M, Bramanti F, Iudice G, Francis DP, Barsotti A, et al. Combined increased chemosensitivity to hypoxia and hypercapnia as a prognosticator in heart failure. Journal of the American College of Cardiology 2009;21:1975-80. - PubMed
Giannoni 2020b
    1. Giannoni A, Gentile F, Sciarrone P, Borrelli C, Pasero G, Mirizzi G, et al. Upright central apnea in patients with heart failure is associated with worse clinical conditions and with a greater risk of cardiac death. Journal of the American College of Cardiology 2020;23:2934-46. - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 24 July 2017. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Hanly 1996
    1. Hanly PJ, Zuberi-Khokhar NS. Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. American Journal of Respiratory and Critical Care Medicine 1996;153:272-6. - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.
Higgins 2022a
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Higgins 2022b
    1. Higgins J, Lasserson T, Chandler J, Tovey D, Churchill R. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Standards for the conduct and reporting of new Cochrane Intervention Reviews, reporting of protocols and the planning, conduct and reporting of updates. Available from community.cochrane.org/mecir-manual.
Jenkinson 1996
    1. Jenkinson C, Layte R, Wright L, Coulter A. Manual and Interpretation Guide for the UK SF-36. Oxford: Health Services Research Unit, 1996.
Johns 1991
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14(6):540-5. - PubMed
Lanfranchi 1999
    1. Lanfranchi PA, Braghiroli A, Bosimini E, Mazzuero G, Colombo R, Donner CF, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999;11:1435-40. - PubMed
Lorenzi‐Filho 2005
    1. Lorenzi-Filho G, Genta PR, Figueiredo AC, Inoue D. Cheyne-Stokes respiration in patients with congestive heart failure: causes and consequences. Clinics 2005;60(4):333-44. - PubMed
Malhotra 2004
    1. Malhotra A, Berry RB, White DP. Central sleep apnea. In: Carney PR, Berry RB, Geyer JD, editors(s). Clinical Sleep Disorders. Philadelphia, PA: Lippincott Williams and Wilkins, 2004:331-46.
Müller 2011
    1. Müller CE, Jacobson KA. Xanthines as adenosine receptor antagonists. Handbook of Experimental Pharmacology 2011;200:151-9. - PMC - PubMed
Nakayama 2002
    1. Nakayama H, Smith CA, Rodman JR, Skatrud JB, Dempsey JA. Effect of ventilatory drive on carbon dioxide sensitivity below eupnea during sleep. American Journal of Respiratory and Critical Care Medicine 2002;165(9):1251-9. - PubMed
Nakayama 2003
    1. Nakayama H, Smith CA, Rodman JR, Skatrud JB, Dempsey JA. Carotid body denervation eliminates apnea in response to transient hypocapnia. Journal of Applied Physiology 2003;94:155-64. - PubMed
Naughton 2016
    1. Naughton MT. Epidemiology of central sleep apnoea in heart failure. International Journal of Cardiology 2016;206:S4-S7. - PubMed
New York Heart Association 1994
    1. New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Boston, MA: Lippincott Williams and Wilkins, 1994.
Oldenburg 2015
    1. Oldenburg O, Wellmann B, Buchholz A, Bitter T, Fox H, Thiem U, et al. Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients. European Heart Journal 2016;21:1695-703. - PubMed
Page 2020
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:71. [DOI: 10.1371/journal.pmed.1000097] - DOI - PMC - PubMed
Peer 2010
    1. Peer A, Lorber A, Suraiya S, Malhotra A, Pillar G. The occurrence of Cheyne-Stokes respiration in congestive heart failure: The effect of age. Frontiers in Psychiatry 2010;1:1-6. - PMC - PubMed
Quadri 2009
    1. Quadri S, Drake C, Hudgel DW. Improvement of idiopathic central sleep apnea with zolpidem. Journal of Clinical Sleep Medicine 2009;5(2):122-9. - PMC - PubMed
RevMan Web 2022 [Computer program]
    1. Review Manager Web (RevMan Web). Version 4.16.1. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.
Sasayama 2009
    1. Sasayama S, Izumi T, Matsuzaki M, Matsumori A, Asanoi H, Momomura S, et al. Improvement of quality of life with nocturnal oxygen therapy in heart failure patients with central sleep apnea. Circulation Journal 2009;73(7):1255-62. - PubMed
Schmickl 2020a
    1. Schmickl CN, Landry SA, Orr JE, Chin K, Murase K, Verbraecken J, et al. Acetazolamide for OSA and central sleep apnea: a comprehensive systematic review and meta-analysis. Chest 2020;158(8):2632-45. - PMC - PubMed
Schmickl 2020b
    1. Schmickl CN, Owens RL, Orr JE, Edwards BA, Malhotra A. Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence. BMJ Open Respiratory Research 2020;7(1):e000557. [PMID: ] - PMC - PubMed
Schumemann 2013
    1. Schumemann H, Brożek J, Guyatt G, Oxman A, editor(s). GRADE Handbook. Available from gdt.gradepro.org/app/handbook/handbook.html 2013.
Schwartz 2021
    1. Schwartz AR, Goldberg LR, McKane S, Morgenthaler TI. Transvenous phrenic nerve stimulation improves central sleep apnea, sleep quality, and quality of life regardless of prior positive airway pressure treatment. Sleep and Breathing 2021;25(4):2053-63. - PMC - PubMed
Simantirakis 2008
    1. Simantirakis EN, Schiza SE, Siafakas NS, Vardas PE. Sleep-disordered breathing in heart failure and the effect of cardiac resynchronization therapy. EP Europace 2008;10:1029-33. - PubMed
Vazir 2007
    1. Vazir A, Hastings PC, Dayer M, et al. A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction. European Journal of Heart Failure 2007;9:243-50. - PubMed
Wilcox 1998
    1. Wilcox I, McNamara SG, Wessendorf T, Willson GN, Piper AJ, Sullivan CE. Prognosis and sleep disordered breathing in heart failure. Thorax 1998;53 Suppl 3:S33-6. - PMC - PubMed

References to other published versions of this review

Riera 2018
    1. Riera R, Latorraca CO, Martimbianco AL, Pacheco RL, Drager LF, Lorenzi-Filho G, et al. Pharmacological treatment for central sleep apnoea in adults. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No: CD012922. [DOI: 10.1002/14651858.CD012922] - DOI - PMC - PubMed

Publication types